{"id": "article-17921_0", "title": "Asthma Medication in Children -- Continuing Education Activity", "content": "Asthma typically presents with a history of respiratory symptoms such as wheezing, shortness of breath, chest tightness, and cough and is characterized by chronic airway inflammation. In adults and older children, the diagnosis of asthma can be confirmed by spirometric evaluation, but asthma\u00a0is a diagnostic challenge in younger children, typically school-aged. A careful history, exam, trigger factors, response to bronchodilator medications, and family history can help establish asthma diagnosis in this age group.", "contents": "Asthma Medication in Children -- Continuing Education Activity. Asthma typically presents with a history of respiratory symptoms such as wheezing, shortness of breath, chest tightness, and cough and is characterized by chronic airway inflammation. In adults and older children, the diagnosis of asthma can be confirmed by spirometric evaluation, but asthma\u00a0is a diagnostic challenge in younger children, typically school-aged. A careful history, exam, trigger factors, response to bronchodilator medications, and family history can help establish asthma diagnosis in this age group."}
{"id": "article-17921_1", "title": "Asthma Medication in Children -- Continuing Education Activity", "content": "This\u00a0course highlights a stepwise approach to interprofessional asthma evaluation and treatment and discusses the medications used for rescue and control. Since the approach to a stepwise\u00a0escalation or de-escalation of medication options differs depending on where the patient presents, these practice guidelines are highlighted.\u00a0Biologics and immunotherapies are also discussed for refractory or chronic presentations, emphasizing adverse drug reactions (ADR) for all classes. Participating clinicians gain a specialized understanding of asthma\u00a0medication in children, involving professionals from allied health professions such as nurses, technicians, and, in particular, pediatricians.", "contents": "Asthma Medication in Children -- Continuing Education Activity. This\u00a0course highlights a stepwise approach to interprofessional asthma evaluation and treatment and discusses the medications used for rescue and control. Since the approach to a stepwise\u00a0escalation or de-escalation of medication options differs depending on where the patient presents, these practice guidelines are highlighted.\u00a0Biologics and immunotherapies are also discussed for refractory or chronic presentations, emphasizing adverse drug reactions (ADR) for all classes. Participating clinicians gain a specialized understanding of asthma\u00a0medication in children, involving professionals from allied health professions such as nurses, technicians, and, in particular, pediatricians."}
{"id": "article-17921_2", "title": "Asthma Medication in Children -- Continuing Education Activity", "content": "Objectives: Interpret\u00a0the signs and symptoms of asthma in the pediatric population. Identify medication classes that\u00a0are used to treat children with asthma. Interpret\u00a0how a stepwise treatment algorithm addresses asthma severity and control. Collaborate to provide\u00a0interprofessional care for\u00a0children with asthma to improve their quality of life. Access free multiple choice questions on this topic.", "contents": "Asthma Medication in Children -- Continuing Education Activity. Objectives: Interpret\u00a0the signs and symptoms of asthma in the pediatric population. Identify medication classes that\u00a0are used to treat children with asthma. Interpret\u00a0how a stepwise treatment algorithm addresses asthma severity and control. Collaborate to provide\u00a0interprofessional care for\u00a0children with asthma to improve their quality of life. Access free multiple choice questions on this topic."}
{"id": "article-17921_3", "title": "Asthma Medication in Children -- Introduction", "content": "Asthma is the most common chronic respiratory disease of childhood, with approximately 14% of children affected worldwide.\u00a0Asthma is characterized by chronic airway inflammation, mucus hypersecretion, and hyper-responsiveness. [1] A triad of wheezing, shortness of breath, and cough\u00a0indicates pediatric asthma. [2] In adults, the diagnosis of asthma can\u00a0be confirmed\u00a0by spirometric evaluation, but managing asthma is\u00a0challenging in pediatric patients. A careful history, exam, trigger factors, response to bronchodilator medications, family history, and FeNO testing can be useful in establishing asthma diagnosis in this age group. [3] Asthma should be suspected\u00a0in children with a history of wheezing\u00a0if the following\u00a0symptoms\u00a0are noted:", "contents": "Asthma Medication in Children -- Introduction. Asthma is the most common chronic respiratory disease of childhood, with approximately 14% of children affected worldwide.\u00a0Asthma is characterized by chronic airway inflammation, mucus hypersecretion, and hyper-responsiveness. [1] A triad of wheezing, shortness of breath, and cough\u00a0indicates pediatric asthma. [2] In adults, the diagnosis of asthma can\u00a0be confirmed\u00a0by spirometric evaluation, but managing asthma is\u00a0challenging in pediatric patients. A careful history, exam, trigger factors, response to bronchodilator medications, family history, and FeNO testing can be useful in establishing asthma diagnosis in this age group. [3] Asthma should be suspected\u00a0in children with a history of wheezing\u00a0if the following\u00a0symptoms\u00a0are noted:"}
{"id": "article-17921_4", "title": "Asthma Medication in Children -- Introduction", "content": "Wheezing or coughing\u00a0exacerbated by\u00a0physical\u00a0exercise or activity Laughing or crying in the absence of apparent\u00a0respiratory infection A history of allergic disease (eczema or allergic rhinitis) or asthma in first-degree relatives Clinical improvement during 2 to 3 months of controller\u00a0treatment and worsening after cessation Symptoms triggered by upper respiratory tract infections, exercise, stress, and environmental exposure to allergens and tobacco smoke. [4] [5]", "contents": "Asthma Medication in Children -- Introduction. Wheezing or coughing\u00a0exacerbated by\u00a0physical\u00a0exercise or activity Laughing or crying in the absence of apparent\u00a0respiratory infection A history of allergic disease (eczema or allergic rhinitis) or asthma in first-degree relatives Clinical improvement during 2 to 3 months of controller\u00a0treatment and worsening after cessation Symptoms triggered by upper respiratory tract infections, exercise, stress, and environmental exposure to allergens and tobacco smoke. [4] [5]"}
{"id": "article-17921_5", "title": "Asthma Medication in Children -- Introduction", "content": "This article primarily reflects pediatric asthma management according to\u00a0NAEPPCC (National Asthma Education and Prevention Program Coordinating Committee) and\u00a0NHLBI (National Heart, Lung, and Blood Institute). [6] The Global Initiative for Asthma (GINA) has recently published guidelines for asthma management. [7]", "contents": "Asthma Medication in Children -- Introduction. This article primarily reflects pediatric asthma management according to\u00a0NAEPPCC (National Asthma Education and Prevention Program Coordinating Committee) and\u00a0NHLBI (National Heart, Lung, and Blood Institute). [6] The Global Initiative for Asthma (GINA) has recently published guidelines for asthma management. [7]"}
{"id": "article-17921_6", "title": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma", "content": "Short-acting beta-2 agonists (SABA): Albuterol (salbutamol), levalbuterol, and terbutaline are used as quick relief therapy or rescue therapy to\u00a0ease symptoms as they reverse bronchoconstriction. [8]", "contents": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma. Short-acting beta-2 agonists (SABA): Albuterol (salbutamol), levalbuterol, and terbutaline are used as quick relief therapy or rescue therapy to\u00a0ease symptoms as they reverse bronchoconstriction. [8]"}
{"id": "article-17921_7", "title": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma", "content": "Long-acting beta-2 agonist (LABA): Formeterol and salmeterol are long-acting beta-2 agonists. Formoterol\u00a0stimulates\u00a0intracellular adenyl cyclase and increases\u00a0cyclic AMP levels, causing the relaxation of bronchial smooth muscles. ICS-formoterol has also been used as a reliever or quick relief\u00a0therapy in GINA guidelines. [7] [9] Long-acting muscarinic antagonist (LAMA): Tiotropium is a long-acting muscarinic antagonist that\u00a0inhibits M3 receptors\u00a0in the lung's smooth muscle, leading to bronchodilation. [10]", "contents": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma. Long-acting beta-2 agonist (LABA): Formeterol and salmeterol are long-acting beta-2 agonists. Formoterol\u00a0stimulates\u00a0intracellular adenyl cyclase and increases\u00a0cyclic AMP levels, causing the relaxation of bronchial smooth muscles. ICS-formoterol has also been used as a reliever or quick relief\u00a0therapy in GINA guidelines. [7] [9] Long-acting muscarinic antagonist (LAMA): Tiotropium is a long-acting muscarinic antagonist that\u00a0inhibits M3 receptors\u00a0in the lung's smooth muscle, leading to bronchodilation. [10]"}
{"id": "article-17921_8", "title": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma", "content": "Inhaled corticosteroids (ICS): Commonly used ICS are budesonide, fluticasone, and mometasone. [11] Inhaled corticosteroids suppress airway inflammation and\u00a0downregulate\u00a0proinflammatory\u00a0mediators. Corticosteroids are also helpful in preventing airway remodeling. In addition, corticosteroids augment the expression of \u03b2-2 receptors in the lung and\u00a0increase responsiveness to SABA and LABA therapy. [12]", "contents": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma. Inhaled corticosteroids (ICS): Commonly used ICS are budesonide, fluticasone, and mometasone. [11] Inhaled corticosteroids suppress airway inflammation and\u00a0downregulate\u00a0proinflammatory\u00a0mediators. Corticosteroids are also helpful in preventing airway remodeling. In addition, corticosteroids augment the expression of \u03b2-2 receptors in the lung and\u00a0increase responsiveness to SABA and LABA therapy. [12]"}
{"id": "article-17921_9", "title": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma", "content": "Systemic corticosteroids: Commonly used systemic corticosteroids include prednisone, dexamethasone, and methylprednisolone.\u00a0Systemic glucocorticoids reduce\u00a0airway hyperresponsiveness\u00a0and airway inflammation, improve lung function and quality of life, and reduce mortality in acute exacerbation. In addition,\u00a0they decrease\u00a0capillary permeability,\u00a0airway edema, and secretions. [13] [14]", "contents": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma. Systemic corticosteroids: Commonly used systemic corticosteroids include prednisone, dexamethasone, and methylprednisolone.\u00a0Systemic glucocorticoids reduce\u00a0airway hyperresponsiveness\u00a0and airway inflammation, improve lung function and quality of life, and reduce mortality in acute exacerbation. In addition,\u00a0they decrease\u00a0capillary permeability,\u00a0airway edema, and secretions. [13] [14]"}
{"id": "article-17921_10", "title": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma", "content": "Leukotriene receptor antagonist (LTRA): The leukotriene modifier, montelukast, is the leukotriene\u00a0antagonist available in either granules or chewable tablets, depending on the age. It is an alternative option, either alone or in combination with inhaled corticosteroids, depending on the level of asthma severity and control. The leukotrienes LTC4, LTD4,\u00a0and LTE4 are\u00a0potent mediators of antigen-induced smooth muscle contraction. Montelukast antagonizes these compounds at their receptor, protecting against bronchoconstriction. In addition,\u00a0leukotrienes\u00a0bind to cysteinyl leukotriene (CysLT) receptors. Montelukast inhibits the CysLT1 receptor and downregulates inflammation. [15] Zafirlukast is also a recommended option. [16] 5-lipoxygenase inhibitor: Zileuton is an inhibitor of 5-lipoxygenase(5-LOX) and inhibits leukotriene formation, reducing airway inflammation. [17]", "contents": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma. Leukotriene receptor antagonist (LTRA): The leukotriene modifier, montelukast, is the leukotriene\u00a0antagonist available in either granules or chewable tablets, depending on the age. It is an alternative option, either alone or in combination with inhaled corticosteroids, depending on the level of asthma severity and control. The leukotrienes LTC4, LTD4,\u00a0and LTE4 are\u00a0potent mediators of antigen-induced smooth muscle contraction. Montelukast antagonizes these compounds at their receptor, protecting against bronchoconstriction. In addition,\u00a0leukotrienes\u00a0bind to cysteinyl leukotriene (CysLT) receptors. Montelukast inhibits the CysLT1 receptor and downregulates inflammation. [15] Zafirlukast is also a recommended option. [16] 5-lipoxygenase inhibitor: Zileuton is an inhibitor of 5-lipoxygenase(5-LOX) and inhibits leukotriene formation, reducing airway inflammation. [17]"}
{"id": "article-17921_11", "title": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma", "content": "Mast cell stabilizers: Mast cell stabilizers used in asthma include sodium cromoglycate (cromolyn sodium) and nedocromil (off-label). Cromolyn sodium inhibits mast cell degranulation after exposure to antigens and inhibits the release of mediators from mast cells.\u00a0Cromolyn also\u00a0reduces bronchospasm induced by exercise, aspirin, cold air, and environmental pollutants. [18] [19]", "contents": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma. Mast cell stabilizers: Mast cell stabilizers used in asthma include sodium cromoglycate (cromolyn sodium) and nedocromil (off-label). Cromolyn sodium inhibits mast cell degranulation after exposure to antigens and inhibits the release of mediators from mast cells.\u00a0Cromolyn also\u00a0reduces bronchospasm induced by exercise, aspirin, cold air, and environmental pollutants. [18] [19]"}
{"id": "article-17921_12", "title": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma", "content": "Methylxanthine: Theophylline inhibits PDE III and adenosine receptors. Theophylline leads to bronchodilation\u00a0mediated by smooth muscle relaxation by inhibiting the phosphodiesterase-III enzyme and has a prophylactic effect. [20]", "contents": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma. Methylxanthine: Theophylline inhibits PDE III and adenosine receptors. Theophylline leads to bronchodilation\u00a0mediated by smooth muscle relaxation by inhibiting the phosphodiesterase-III enzyme and has a prophylactic effect. [20]"}
{"id": "article-17921_13", "title": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma", "content": "Anti-IgE antibody: Omalizumab is a monoclonal\u00a0antibody that\u00a0inhibits the binding of IgE to the IgE receptor on the surface of mast cells and prevents the mast cell degranulation and release of inflammatory mediators such as IL-4, IL-5, and IL-13. [21]", "contents": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma. Anti-IgE antibody: Omalizumab is a monoclonal\u00a0antibody that\u00a0inhibits the binding of IgE to the IgE receptor on the surface of mast cells and prevents the mast cell degranulation and release of inflammatory mediators such as IL-4, IL-5, and IL-13. [21]"}
{"id": "article-17921_14", "title": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma", "content": "Anti-interleukin-5 monoclonal antibody: Mepolizumab is an IL-5 antagonist. IL-5 is the primary cytokine responsible for eosinophils' maturation, recruitment, and activation. Administration of mepolizumab leads to decreased eosinophilia and reduced airway inflammation. [22]", "contents": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma. Anti-interleukin-5 monoclonal antibody: Mepolizumab is an IL-5 antagonist. IL-5 is the primary cytokine responsible for eosinophils' maturation, recruitment, and activation. Administration of mepolizumab leads to decreased eosinophilia and reduced airway inflammation. [22]"}
{"id": "article-17921_15", "title": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma", "content": "Anti-interleukin-5 receptor alpha monoclonal antibody: Benralizumab binds to the \u03b1 subunit of the interleukin-5 receptor, decreasing eosinophil activation.\u00a0Benralizumab also decreases antibody-dependent cell-mediated cytotoxicity. [23]", "contents": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma. Anti-interleukin-5 receptor alpha monoclonal antibody: Benralizumab binds to the \u03b1 subunit of the interleukin-5 receptor, decreasing eosinophil activation.\u00a0Benralizumab also decreases antibody-dependent cell-mediated cytotoxicity. [23]"}
{"id": "article-17921_16", "title": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma", "content": "Anti-interleukin-4 receptor \u03b1 monoclonal antibody: Dupilumab is an IgG4 antibody that inhibits IL-4 and IL-13 signaling by binding to the IL-4R \u03b1 subunit, inhibiting the\u00a0release of proinflammatory cytokines and chemokines. [24]", "contents": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma. Anti-interleukin-4 receptor \u03b1 monoclonal antibody: Dupilumab is an IgG4 antibody that inhibits IL-4 and IL-13 signaling by binding to the IL-4R \u03b1 subunit, inhibiting the\u00a0release of proinflammatory cytokines and chemokines. [24]"}
{"id": "article-17921_17", "title": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma", "content": "Immunotherapy: Subcutaneous immunotherapy (SCIT) for asthma is the administration of specific exogenous aeroallergens with demonstrated sensitivity. Prerequisites are documented hypersensitivity to the specific allergen by skin testing (after 15 to 20 minutes) and antigen-specific IgE antibodies in a blood sample. [25]", "contents": "Asthma Medication in Children -- Introduction -- Medications, Biologics, and Immunotherapy for Pediatric Asthma. Immunotherapy: Subcutaneous immunotherapy (SCIT) for asthma is the administration of specific exogenous aeroallergens with demonstrated sensitivity. Prerequisites are documented hypersensitivity to the specific allergen by skin testing (after 15 to 20 minutes) and antigen-specific IgE antibodies in a blood sample. [25]"}
{"id": "article-17921_18", "title": "Asthma Medication in Children -- Function -- Essential Components of Management of Asthma in the Pediatric Population", "content": "Diagnosis of asthma Stepwise approach for management of asthma Emphasis on the use of preferred\u00a0treatment at\u00a0each step SMART (single maintenance and reliever therapy) before proceeding to a higher-step level of treatment. [26] Achieve adequate symptom control Management of asthma exacerbation Minimize\u00a0adverse drug reactions Shared decision-making\u00a0accounting for\u00a0risks vs. benefits and personal preferences Patient education\u00a0regarding inhaler techniques Improving patient adherence Assessment of environmental triggers Evaluation\u00a0and management of comorbidities Overall reduction in mortality Assessment of quality of life by using a validated questionnaire (Pediatric Asthma Quality of Life Questionnaire) Consultation with a pulmonologist/immunologist if the patient requires care at step 3 or higher. [27]", "contents": "Asthma Medication in Children -- Function -- Essential Components of Management of Asthma in the Pediatric Population. Diagnosis of asthma Stepwise approach for management of asthma Emphasis on the use of preferred\u00a0treatment at\u00a0each step SMART (single maintenance and reliever therapy) before proceeding to a higher-step level of treatment. [26] Achieve adequate symptom control Management of asthma exacerbation Minimize\u00a0adverse drug reactions Shared decision-making\u00a0accounting for\u00a0risks vs. benefits and personal preferences Patient education\u00a0regarding inhaler techniques Improving patient adherence Assessment of environmental triggers Evaluation\u00a0and management of comorbidities Overall reduction in mortality Assessment of quality of life by using a validated questionnaire (Pediatric Asthma Quality of Life Questionnaire) Consultation with a pulmonologist/immunologist if the patient requires care at step 3 or higher. [27]"}
{"id": "article-17921_19", "title": "Asthma Medication in Children -- Function", "content": "According to\u00a0NAEPPCC (National Asthma Education and Prevention Program Coordinating Committee) and\u00a0NHLBI (National Heart, Lung, and Blood Institute), treatment regimens\u00a0by age group are described below.\u00a0The following section highlights a stepwise approach to asthma medications used for rescue and control. Step therapy is based on the domains of severity and control. [28]", "contents": "Asthma Medication in Children -- Function. According to\u00a0NAEPPCC (National Asthma Education and Prevention Program Coordinating Committee) and\u00a0NHLBI (National Heart, Lung, and Blood Institute), treatment regimens\u00a0by age group are described below.\u00a0The following section highlights a stepwise approach to asthma medications used for rescue and control. Step therapy is based on the domains of severity and control. [28]"}
{"id": "article-17921_20", "title": "Asthma Medication in Children -- Function -- Asthma Management in the Age Group\u00a00 to 4 years", "content": "Step 1: The preferred therapy is PRN SABA (short-acting \u03b22-agonist). In patients with recurrent wheezing, a short (7 to 10 days) course of ICS with PRN\u00a0SABA is recommended at the onset of respiratory tract infection. The\u00a0strategy of initiating ICS and PRN SABA decreases asthma exacerbations and reduces\u00a0the use of\u00a0systemic corticosteroids. Step 2: Daily low-dose ICS (inhaled corticosteroids) as controller therapy and PRN SABA as quick relief therapy. An alternative regimen is daily montelukast or cromolyn and PRN SABA. Step 3: Daily medium dose ICS as controller therapy and PRN SABA for quick relief therapy. Step 4: Daily medium dose ICS-LABA (long-acting \u03b22-agonist) as controller therapy and PRN SABA for quick relief therapy. The alternative regimen is a daily medium dose of ICS + montelukast and PRN SABA. Step 5: Daily high-dose ICS-LABA as controller therapy and PRN SABA for\u00a0quick relief therapy. The alternative regimen is a daily\u00a0high dose of ICS + montelukast and PRN SABA.", "contents": "Asthma Medication in Children -- Function -- Asthma Management in the Age Group\u00a00 to 4 years. Step 1: The preferred therapy is PRN SABA (short-acting \u03b22-agonist). In patients with recurrent wheezing, a short (7 to 10 days) course of ICS with PRN\u00a0SABA is recommended at the onset of respiratory tract infection. The\u00a0strategy of initiating ICS and PRN SABA decreases asthma exacerbations and reduces\u00a0the use of\u00a0systemic corticosteroids. Step 2: Daily low-dose ICS (inhaled corticosteroids) as controller therapy and PRN SABA as quick relief therapy. An alternative regimen is daily montelukast or cromolyn and PRN SABA. Step 3: Daily medium dose ICS as controller therapy and PRN SABA for quick relief therapy. Step 4: Daily medium dose ICS-LABA (long-acting \u03b22-agonist) as controller therapy and PRN SABA for quick relief therapy. The alternative regimen is a daily medium dose of ICS + montelukast and PRN SABA. Step 5: Daily high-dose ICS-LABA as controller therapy and PRN SABA for\u00a0quick relief therapy. The alternative regimen is a daily\u00a0high dose of ICS + montelukast and PRN SABA."}
{"id": "article-17921_21", "title": "Asthma Medication in Children -- Function", "content": "Step 6: Daily high-dose ICS-LABA + oral systemic corticosteroid and PRN SABA. The alternative regimen is daily high-dose ICS + montelukast + oral systemic corticosteroid and PRN SABA.", "contents": "Asthma Medication in Children -- Function. Step 6: Daily high-dose ICS-LABA + oral systemic corticosteroid and PRN SABA. The alternative regimen is daily high-dose ICS + montelukast + oral systemic corticosteroid and PRN SABA."}
{"id": "article-17921_22", "title": "Asthma Medication in Children -- Function", "content": "Albuterol (salbutamol) or levalbuterol is the preferred drug for SABA. LABA\u00a0medications are formoterol and salmeterol, with formoterol being the preferred drug. Inhaled corticosteroids (ICS) are budesonide, beclomethasone, and fluticasone. [29] The most commonly used\u00a0combination\u00a0is\u00a0ICS and formoterol, preferably in a single inhaler.\u00a0FDA has issued a boxed warning for montelukast due to\u00a0neuropsychiatric adverse events. [30] Reassess the patient in 4 to 6 weeks and step up if required. The clinician can consider stepping down therapy for patients with well-controlled asthma for >\u00a03 consecutive months.", "contents": "Asthma Medication in Children -- Function. Albuterol (salbutamol) or levalbuterol is the preferred drug for SABA. LABA\u00a0medications are formoterol and salmeterol, with formoterol being the preferred drug. Inhaled corticosteroids (ICS) are budesonide, beclomethasone, and fluticasone. [29] The most commonly used\u00a0combination\u00a0is\u00a0ICS and formoterol, preferably in a single inhaler.\u00a0FDA has issued a boxed warning for montelukast due to\u00a0neuropsychiatric adverse events. [30] Reassess the patient in 4 to 6 weeks and step up if required. The clinician can consider stepping down therapy for patients with well-controlled asthma for >\u00a03 consecutive months."}
{"id": "article-17921_23", "title": "Asthma Medication in Children -- Function -- Asthma Management in the Age Group 5 to 11 years", "content": "Step 1: PRN SABA Step 2: Daily low-dose ICS as controller therapy\u00a0and\u00a0PRN SABA as quick relief therapy. Daily therapy with LTRA, cromolyn, nedocromil, theophylline, and\u00a0PRN SABA are alternative regimens. Step 3: Daily\u00a0combination of low-dose\u00a0ICS-formoterol as controller and quick relief therapy. The alternative\u00a0regimen is daily medium-dose\u00a0ICS and PRN SABA. Another alternative regimen is daily low-dose\u00a0ICS-LABA, daily low-dose\u00a0ICS + LTRA, or daily low-dose ICS + theophylline and PRN SABA. Step 4: Daily combination of\u00a0medium-dose\u00a0ICS-formoterol as controller therapy and medium-dose\u00a0ICS-formoterol PRN for\u00a0quick relief therapy. The alternative regimen is a daily medium dose of ICS-LABA as controller therapy and PRN SABA as quick relief therapy. Another alternative regimen is daily medium dose\u00a0ICS + LTRA or daily medium dose\u00a0ICS + theophylline as controller therapy and PRN SABA as quick relief therapy.", "contents": "Asthma Medication in Children -- Function -- Asthma Management in the Age Group 5 to 11 years. Step 1: PRN SABA Step 2: Daily low-dose ICS as controller therapy\u00a0and\u00a0PRN SABA as quick relief therapy. Daily therapy with LTRA, cromolyn, nedocromil, theophylline, and\u00a0PRN SABA are alternative regimens. Step 3: Daily\u00a0combination of low-dose\u00a0ICS-formoterol as controller and quick relief therapy. The alternative\u00a0regimen is daily medium-dose\u00a0ICS and PRN SABA. Another alternative regimen is daily low-dose\u00a0ICS-LABA, daily low-dose\u00a0ICS + LTRA, or daily low-dose ICS + theophylline and PRN SABA. Step 4: Daily combination of\u00a0medium-dose\u00a0ICS-formoterol as controller therapy and medium-dose\u00a0ICS-formoterol PRN for\u00a0quick relief therapy. The alternative regimen is a daily medium dose of ICS-LABA as controller therapy and PRN SABA as quick relief therapy. Another alternative regimen is daily medium dose\u00a0ICS + LTRA or daily medium dose\u00a0ICS + theophylline as controller therapy and PRN SABA as quick relief therapy."}
{"id": "article-17921_24", "title": "Asthma Medication in Children -- Function", "content": "Step 5: Daily high-dose ICS-LABA as controller therapy and PRN SABA for\u00a0quick relief therapy. An alternative regimen is a daily\u00a0high dose of ICS + LTRA and PRN SABA. Another alternative regimen is daily high-dose ICS + theophylline and PRN SABA. Step 6: Daily high-dose ICS-LABA + oral systemic corticosteroid as controller therapy and PRN SABA. An alternative regimen is daily high-dose ICS + LTRA + oral systemic corticosteroid and PRN SABA. Another alternative regimen of daily high-dose ICS + theophylline + oral systemic corticosteroid and PRN SABA", "contents": "Asthma Medication in Children -- Function. Step 5: Daily high-dose ICS-LABA as controller therapy and PRN SABA for\u00a0quick relief therapy. An alternative regimen is a daily\u00a0high dose of ICS + LTRA and PRN SABA. Another alternative regimen is daily high-dose ICS + theophylline and PRN SABA. Step 6: Daily high-dose ICS-LABA + oral systemic corticosteroid as controller therapy and PRN SABA. An alternative regimen is daily high-dose ICS + LTRA + oral systemic corticosteroid and PRN SABA. Another alternative regimen of daily high-dose ICS + theophylline + oral systemic corticosteroid and PRN SABA"}
{"id": "article-17921_25", "title": "Asthma Medication in Children -- Function", "content": "For Steps 2 to 4, there is a subcutaneous\u00a0immunotherapy as an adjunct therapy to standard\u00a0treatment in\u00a0patients \u2265 5 years of age. Subcutaneous immunotherapy (SCIT) is recommended as an adjunct treatment for\u00a0patients\u00a0with\u00a0established allergic sensitization and evidence of worsening asthma symptoms\u00a0following exposure\u00a0to the relevant antigens. [31] For Steps 5 and 6, omalizumab, an\u00a0anti-immunoglobulin E (IgE) monoclonal antibody, should be considered; other biologic therapies are not FDA-approved for the age group 5 to 11 years. [32] FDA age ranges for infancy are birth\u00a0to\u00a02 years; childhood, 2 to 12 years; and adolescence, from 12 to 21. [33] This review also includes asthma management in the adolescent age group.", "contents": "Asthma Medication in Children -- Function. For Steps 2 to 4, there is a subcutaneous\u00a0immunotherapy as an adjunct therapy to standard\u00a0treatment in\u00a0patients \u2265 5 years of age. Subcutaneous immunotherapy (SCIT) is recommended as an adjunct treatment for\u00a0patients\u00a0with\u00a0established allergic sensitization and evidence of worsening asthma symptoms\u00a0following exposure\u00a0to the relevant antigens. [31] For Steps 5 and 6, omalizumab, an\u00a0anti-immunoglobulin E (IgE) monoclonal antibody, should be considered; other biologic therapies are not FDA-approved for the age group 5 to 11 years. [32] FDA age ranges for infancy are birth\u00a0to\u00a02 years; childhood, 2 to 12 years; and adolescence, from 12 to 21. [33] This review also includes asthma management in the adolescent age group."}
{"id": "article-17921_26", "title": "Asthma Medication in Children -- Function -- Asthma Management for Ages >12 years", "content": "Step 1: PRN SABA Step 2: Daily low-dose ICS\u00a0and PRN SABA\u00a0or\u00a0PRN concomitant\u00a0ICS and SABA. An alternative regimen is daily LTRA and\u00a0PRN SABA. An additional alternative\u00a0regimen\u00a0is cromolyn or nedocromil or zileuton or theophylline and\u00a0PRN SABA (less preferred\u00a0for use in the\u00a0United States due to potential adverse drug reactions). Step 3: Daily and PRN\u00a0combination\u00a0low-dose ICS-formoterol. The alternative strategy is daily medium-dose\u00a0ICS and PRN\u00a0SABA. An alternative regimen is daily low-dose\u00a0ICS + (LABA/LAMA/LTRA) and PRN SABA. LAMA is a long-acting muscarinic antagonist like tiotropium. [34] The optional\u00a0regimen is daily low-dose ICS\u00a0+ theophylline or zileuton and\u00a0PRN SABA (less preferred\u00a0for use in the\u00a0US due to potential adverse drug reactions).", "contents": "Asthma Medication in Children -- Function -- Asthma Management for Ages >12 years. Step 1: PRN SABA Step 2: Daily low-dose ICS\u00a0and PRN SABA\u00a0or\u00a0PRN concomitant\u00a0ICS and SABA. An alternative regimen is daily LTRA and\u00a0PRN SABA. An additional alternative\u00a0regimen\u00a0is cromolyn or nedocromil or zileuton or theophylline and\u00a0PRN SABA (less preferred\u00a0for use in the\u00a0United States due to potential adverse drug reactions). Step 3: Daily and PRN\u00a0combination\u00a0low-dose ICS-formoterol. The alternative strategy is daily medium-dose\u00a0ICS and PRN\u00a0SABA. An alternative regimen is daily low-dose\u00a0ICS + (LABA/LAMA/LTRA) and PRN SABA. LAMA is a long-acting muscarinic antagonist like tiotropium. [34] The optional\u00a0regimen is daily low-dose ICS\u00a0+ theophylline or zileuton and\u00a0PRN SABA (less preferred\u00a0for use in the\u00a0US due to potential adverse drug reactions)."}
{"id": "article-17921_27", "title": "Asthma Medication in Children -- Function", "content": "Step 4: Daily and PRN\u00a0combination\u00a0medium-dose\u00a0ICS-formoterol. The alternative regimen is daily medium-dose ICS-LABA or medium-dose ICS + LAMA and\u00a0PRN SABA. The optional regimen is daily medium dose\u00a0ICS + (LTRA or theophylline or zileuton) and PRN SABA (less preferred\u00a0for use in the US due to potential adverse drug reactions). Step 5: Daily medium to high\u00a0dose ICS-LABA combination +\u00a0LAMA and\u00a0PRN SABA. The alternative regimen is medium to high\u00a0dose ICS-LABA\u00a0or daily high-dose\u00a0ICS + LTRA and\u00a0PRN SABA. Step 6: Daily high-dose\u00a0ICS-LABA +\u00a0oral systemic\u00a0corticosteroids +\u00a0PRN SABA. For steps 2 to 4, subcutaneous immunotherapy (SCIT) is recommended for patients >5 years of age, as described above.", "contents": "Asthma Medication in Children -- Function. Step 4: Daily and PRN\u00a0combination\u00a0medium-dose\u00a0ICS-formoterol. The alternative regimen is daily medium-dose ICS-LABA or medium-dose ICS + LAMA and\u00a0PRN SABA. The optional regimen is daily medium dose\u00a0ICS + (LTRA or theophylline or zileuton) and PRN SABA (less preferred\u00a0for use in the US due to potential adverse drug reactions). Step 5: Daily medium to high\u00a0dose ICS-LABA combination +\u00a0LAMA and\u00a0PRN SABA. The alternative regimen is medium to high\u00a0dose ICS-LABA\u00a0or daily high-dose\u00a0ICS + LTRA and\u00a0PRN SABA. Step 6: Daily high-dose\u00a0ICS-LABA +\u00a0oral systemic\u00a0corticosteroids +\u00a0PRN SABA. For steps 2 to 4, subcutaneous immunotherapy (SCIT) is recommended for patients >5 years of age, as described above."}
{"id": "article-17921_28", "title": "Asthma Medication in Children -- Function", "content": "For Steps 5 and 6, biologics may be considered\u00a0(e.g., anti-IgE, anti-IL4, anti-IL13, anti-IL5, anti-IL5R). [35] However, no\u00a0specific recommendations\u00a0have been made. Consultation with an asthma specialist or immunologist is recommended.", "contents": "Asthma Medication in Children -- Function. For Steps 5 and 6, biologics may be considered\u00a0(e.g., anti-IgE, anti-IL4, anti-IL13, anti-IL5, anti-IL5R). [35] However, no\u00a0specific recommendations\u00a0have been made. Consultation with an asthma specialist or immunologist is recommended."}
{"id": "article-17921_29", "title": "Asthma Medication in Children -- Function -- SMART (Single Maintenance and Reliever Therapy)", "content": "The SMART approach is a treatment with ICS and LABA (formoterol) for daily and rescue treatment. It is advised as the choice of therapy for\u00a0patients\u00a0\u2265\u00a04 years (not well-controlled on a low- or medium-dose daily ICS alone). Formoterol is the LABA of choice because it has a rapid onset of action and can be used more than twice daily. SMART is a technique for decreasing exacerbation and\u00a0total corticosteroid use. There\u00a0is\u00a0a lower risk of growth suppression\u00a0in patients\u00a0taking SMART versus daily higher-dose ICS treatment. Consequently, patients with uncontrolled asthma on daily ICS-LABA maintenance therapy should be considered for\u00a0SMART before moving to a higher-step level of treatment. [26]", "contents": "Asthma Medication in Children -- Function -- SMART (Single Maintenance and Reliever Therapy). The SMART approach is a treatment with ICS and LABA (formoterol) for daily and rescue treatment. It is advised as the choice of therapy for\u00a0patients\u00a0\u2265\u00a04 years (not well-controlled on a low- or medium-dose daily ICS alone). Formoterol is the LABA of choice because it has a rapid onset of action and can be used more than twice daily. SMART is a technique for decreasing exacerbation and\u00a0total corticosteroid use. There\u00a0is\u00a0a lower risk of growth suppression\u00a0in patients\u00a0taking SMART versus daily higher-dose ICS treatment. Consequently, patients with uncontrolled asthma on daily ICS-LABA maintenance therapy should be considered for\u00a0SMART before moving to a higher-step level of treatment. [26]"}
{"id": "article-17921_30", "title": "Asthma Medication in Children -- Function -- Clinical Utility of FeNO Testing", "content": "Nitric oxide can be calculated in exhaled breath and estimate the level of airway\u00a0inflammation. In individuals with asthma, fractional exhaled nitric oxide (FeNO) is\u00a0a useful\u00a0indicator of airway type 2 bronchial or eosinophilic inflammation. FeNO is a quantitative, noninvasive, straightforward, and safe technique for estimating airway inflammation. In patients\u00a0ages\u00a05 years and older diagnosed with asthma after extensive evaluation,\u00a0FeNO measurement can help as an adjunct to the\u00a0diagnosis and response to therapy. It is\u00a0particularly\u00a0useful in patients whose\u00a0spirometry testing cannot be performed accurately. FeNO levels > 50 ppb in adults or FeNO levels\u00a0>\u00a035 ppb in children aged 5 to 12 years are\u00a0consistent with T2 inflammation, and\u00a0these patients are more likely to respond to corticosteroid treatment. ATS (The American Thoracic Society) clinical practice guidelines also endorse FeNO as an adjunct for diagnosis and determining the probability of corticosteroid responsiveness. [36]", "contents": "Asthma Medication in Children -- Function -- Clinical Utility of FeNO Testing. Nitric oxide can be calculated in exhaled breath and estimate the level of airway\u00a0inflammation. In individuals with asthma, fractional exhaled nitric oxide (FeNO) is\u00a0a useful\u00a0indicator of airway type 2 bronchial or eosinophilic inflammation. FeNO is a quantitative, noninvasive, straightforward, and safe technique for estimating airway inflammation. In patients\u00a0ages\u00a05 years and older diagnosed with asthma after extensive evaluation,\u00a0FeNO measurement can help as an adjunct to the\u00a0diagnosis and response to therapy. It is\u00a0particularly\u00a0useful in patients whose\u00a0spirometry testing cannot be performed accurately. FeNO levels > 50 ppb in adults or FeNO levels\u00a0>\u00a035 ppb in children aged 5 to 12 years are\u00a0consistent with T2 inflammation, and\u00a0these patients are more likely to respond to corticosteroid treatment. ATS (The American Thoracic Society) clinical practice guidelines also endorse FeNO as an adjunct for diagnosis and determining the probability of corticosteroid responsiveness. [36]"}
{"id": "article-17921_31", "title": "Asthma Medication in Children -- Issues of Concern -- Adverse Drug Reactions (ADR)", "content": "Inhaled \u03b2-2 agonist: Common adverse drug reactions of SABA and LABA include tremors, tachycardia, and palpitations. These adverse effects are seen more often during initial exposure. [37] A boxed warning advises that long-acting \u03b2-2 agonists such as salmeterol or formoterol without ICS increase the risk of asthma-related death.", "contents": "Asthma Medication in Children -- Issues of Concern -- Adverse Drug Reactions (ADR). Inhaled \u03b2-2 agonist: Common adverse drug reactions of SABA and LABA include tremors, tachycardia, and palpitations. These adverse effects are seen more often during initial exposure. [37] A boxed warning advises that long-acting \u03b2-2 agonists such as salmeterol or formoterol without ICS increase the risk of asthma-related death."}
{"id": "article-17921_32", "title": "Asthma Medication in Children -- Issues of Concern -- Adverse Drug Reactions (ADR)", "content": "Inhaled corticosteroids: Oropharyngeal candidiasis and dysphonia are the most\u00a0commonly\u00a0documented ICS-associated ADR. Using a spacer device and rinsing the mouth after using an ICS decreases the risk of oral thrush. [38] Long-acting muscarinic antagonist: The anticholinergic adverse effects of LAMA (tiotropium)\u00a0are dry mouth, constipation, blurring of vision, and urinary difficulty or retention. [39]", "contents": "Asthma Medication in Children -- Issues of Concern -- Adverse Drug Reactions (ADR). Inhaled corticosteroids: Oropharyngeal candidiasis and dysphonia are the most\u00a0commonly\u00a0documented ICS-associated ADR. Using a spacer device and rinsing the mouth after using an ICS decreases the risk of oral thrush. [38] Long-acting muscarinic antagonist: The anticholinergic adverse effects of LAMA (tiotropium)\u00a0are dry mouth, constipation, blurring of vision, and urinary difficulty or retention. [39]"}
{"id": "article-17921_33", "title": "Asthma Medication in Children -- Issues of Concern -- Adverse Drug Reactions (ADR)", "content": "Systemic corticosteroids: Vomiting, behavioral changes, sleep disturbance, and increased risk of infections are common with short-course oral corticosteroids in children. [40] Long-term\u00a0ADR of systemic corticosteroids includes osteoporosis, diabetes, adrenal insufficiency, delayed wound healing, cataracts, aseptic joint necrosis,\u00a0GI bleeding, and growth suppression. [41] [42] [43]", "contents": "Asthma Medication in Children -- Issues of Concern -- Adverse Drug Reactions (ADR). Systemic corticosteroids: Vomiting, behavioral changes, sleep disturbance, and increased risk of infections are common with short-course oral corticosteroids in children. [40] Long-term\u00a0ADR of systemic corticosteroids includes osteoporosis, diabetes, adrenal insufficiency, delayed wound healing, cataracts, aseptic joint necrosis,\u00a0GI bleeding, and growth suppression. [41] [42] [43]"}
{"id": "article-17921_34", "title": "Asthma Medication in Children -- Issues of Concern -- Adverse Drug Reactions (ADR)", "content": "Leukotriene receptor antagonist: The most serious adverse event associated with montelukast therapy is neuropsychiatric adverse effects (FDA boxed warning). Neuropsychiatric\u00a0ADR ranges from insomnia to suicidal ideation. [2] [30] Zafirlukast is associated with hepatotoxicity. [44]", "contents": "Asthma Medication in Children -- Issues of Concern -- Adverse Drug Reactions (ADR). Leukotriene receptor antagonist: The most serious adverse event associated with montelukast therapy is neuropsychiatric adverse effects (FDA boxed warning). Neuropsychiatric\u00a0ADR ranges from insomnia to suicidal ideation. [2] [30] Zafirlukast is associated with hepatotoxicity. [44]"}
{"id": "article-17921_35", "title": "Asthma Medication in Children -- Issues of Concern -- Adverse Drug Reactions (ADR)", "content": "Mast cell stabilizers: Mast cell stabilizers used in asthma are cromolyn and nedocromil. [18] Adverse effects associated with cromolyn may include throat irritation, sneezing, and an unpleasant taste. [45] ADR due to nedocromil\u00a0are an unpleasant taste, headache, and cough. [46]", "contents": "Asthma Medication in Children -- Issues of Concern -- Adverse Drug Reactions (ADR). Mast cell stabilizers: Mast cell stabilizers used in asthma are cromolyn and nedocromil. [18] Adverse effects associated with cromolyn may include throat irritation, sneezing, and an unpleasant taste. [45] ADR due to nedocromil\u00a0are an unpleasant taste, headache, and cough. [46]"}
{"id": "article-17921_36", "title": "Asthma Medication in Children -- Issues of Concern -- Adverse Drug Reactions (ADR)", "content": "Theophylline: Common adverse drug reactions include nausea, vomiting, and headaches. At higher concentrations, seizures and cardiac arrhythmias, including\u00a0multifocal atrial tachycardia, have been reported. [47] [20] Omalizumab: The most common adverse effect is skin inflammation at the injection site. A potentially life-threatening and rare adverse drug reaction\u00a0is anaphylaxis. [48] Dupilumab: Common ADR are mild injection site reactions and eosinophilia. Mepolizumab: Headache and bronchitis are common. Benralizumab: ADR associated with are headache, fever, nasopharyngitis, and sinusitis. [2]", "contents": "Asthma Medication in Children -- Issues of Concern -- Adverse Drug Reactions (ADR). Theophylline: Common adverse drug reactions include nausea, vomiting, and headaches. At higher concentrations, seizures and cardiac arrhythmias, including\u00a0multifocal atrial tachycardia, have been reported. [47] [20] Omalizumab: The most common adverse effect is skin inflammation at the injection site. A potentially life-threatening and rare adverse drug reaction\u00a0is anaphylaxis. [48] Dupilumab: Common ADR are mild injection site reactions and eosinophilia. Mepolizumab: Headache and bronchitis are common. Benralizumab: ADR associated with are headache, fever, nasopharyngitis, and sinusitis. [2]"}
{"id": "article-17921_37", "title": "Asthma Medication in Children -- Issues of Concern -- Adverse Drug Reactions (ADR)", "content": "Subcutaneous immunotherapy (SCIT): SCIT should be administered under direct supervision\u00a0due to the potential for anaphylaxis, urticaria, rhinitis, nausea, diarrhea, vomiting, hypotension, and arrhythmias. Consequently, a 30-minute observational period\u00a0is needed after\u00a0each SCIT injection. [6]", "contents": "Asthma Medication in Children -- Issues of Concern -- Adverse Drug Reactions (ADR). Subcutaneous immunotherapy (SCIT): SCIT should be administered under direct supervision\u00a0due to the potential for anaphylaxis, urticaria, rhinitis, nausea, diarrhea, vomiting, hypotension, and arrhythmias. Consequently, a 30-minute observational period\u00a0is needed after\u00a0each SCIT injection. [6]"}
{"id": "article-17921_38", "title": "Asthma Medication in Children -- Issues of Concern -- Asthma Phenotype", "content": "Global Initiative for Asthma (GINA) guidelines show that population-level recommendations depend on type II or non-type II phenotypes. Type II inflammation is found in patients with severe asthma and atopy. It is associated with allergic conditions such as nasal polyposis and atopic dermatitis. Elevated serum, sputum eosinophils, and increased FeNO characterize type 2 inflammation. Management includes optimal use of ICS and targeted biologics. Dupilumab is indicated in patients with\u00a0severe\u00a0eosinophilia or type 2 asthma uncontrolled on high-dose ICS-LABA. Pediatric patients with persistently elevated IgE levels\u00a0respond well to omalizumab. [49] [7]", "contents": "Asthma Medication in Children -- Issues of Concern -- Asthma Phenotype. Global Initiative for Asthma (GINA) guidelines show that population-level recommendations depend on type II or non-type II phenotypes. Type II inflammation is found in patients with severe asthma and atopy. It is associated with allergic conditions such as nasal polyposis and atopic dermatitis. Elevated serum, sputum eosinophils, and increased FeNO characterize type 2 inflammation. Management includes optimal use of ICS and targeted biologics. Dupilumab is indicated in patients with\u00a0severe\u00a0eosinophilia or type 2 asthma uncontrolled on high-dose ICS-LABA. Pediatric patients with persistently elevated IgE levels\u00a0respond well to omalizumab. [49] [7]"}
{"id": "article-17921_39", "title": "Asthma Medication in Children -- Issues of Concern -- Inadequate Control", "content": "Increased\u00a0use of albuterol (salbutamol) for >2 days a week for symptom relief typically indicates inadequate control and may require a step-up in treatment.", "contents": "Asthma Medication in Children -- Issues of Concern -- Inadequate Control. Increased\u00a0use of albuterol (salbutamol) for >2 days a week for symptom relief typically indicates inadequate control and may require a step-up in treatment."}
{"id": "article-17921_40", "title": "Asthma Medication in Children -- Issues of Concern -- Inhaler Technique", "content": "A systemic review concluded that using\u00a0turbuhaler and diskus inhalers is better than metered-dose inhalers (MDI) in children. The best technique is when MDIs are used with spacers. Consequently, pressured MDI with a spacer is the preferred device in children. Different-sized masks are available. A valved holding chamber\u00a0enables the\u00a0diffusion of medication\u00a0and\u00a0the coordination of actuation. A nebulizer with a facemask or mouthpiece\u00a0is effective in children who cannot be taught how to use a spacer device. Not every medication is available as a nebulizer agent. [50]", "contents": "Asthma Medication in Children -- Issues of Concern -- Inhaler Technique. A systemic review concluded that using\u00a0turbuhaler and diskus inhalers is better than metered-dose inhalers (MDI) in children. The best technique is when MDIs are used with spacers. Consequently, pressured MDI with a spacer is the preferred device in children. Different-sized masks are available. A valved holding chamber\u00a0enables the\u00a0diffusion of medication\u00a0and\u00a0the coordination of actuation. A nebulizer with a facemask or mouthpiece\u00a0is effective in children who cannot be taught how to use a spacer device. Not every medication is available as a nebulizer agent. [50]"}
{"id": "article-17921_41", "title": "Asthma Medication in Children -- Issues of Concern -- Compliance to Pharmacotherapy", "content": "Inadequate adherence in children with asthma is a\u00a0leading cause of asthma attacks and a factor in asthma deaths. Subjective and objective measures for monitoring compliance have limitations; electronic monitoring devices (EMDs) can be considered. [51]", "contents": "Asthma Medication in Children -- Issues of Concern -- Compliance to Pharmacotherapy. Inadequate adherence in children with asthma is a\u00a0leading cause of asthma attacks and a factor in asthma deaths. Subjective and objective measures for monitoring compliance have limitations; electronic monitoring devices (EMDs) can be considered. [51]"}
{"id": "article-17921_42", "title": "Asthma Medication in Children -- Issues of Concern -- Asthma Exacerbation", "content": "In severe cases, management of exacerbations includes\u00a0bronchodilators, oxygen therapy, glucocorticosteroids, and mechanical ventilation. Adding a LAMA (tiotropium) to ICS-LABA for\u00a0patients with uncontrolled asthma on ICS-LABA enhances asthma control. Systemic corticosteroids may still be required depending on the patient's presentation.", "contents": "Asthma Medication in Children -- Issues of Concern -- Asthma Exacerbation. In severe cases, management of exacerbations includes\u00a0bronchodilators, oxygen therapy, glucocorticosteroids, and mechanical ventilation. Adding a LAMA (tiotropium) to ICS-LABA for\u00a0patients with uncontrolled asthma on ICS-LABA enhances asthma control. Systemic corticosteroids may still be required depending on the patient's presentation."}
{"id": "article-17921_43", "title": "Asthma Medication in Children -- Issues of Concern -- Asthma Exacerbation", "content": "In young children, suspension is better tolerated and accepted than tablets. In addition, for children aged 0 to 4 years with a history of previous severe exacerbations, a short course of oral systemic corticosteroids is advised.\u00a0Frequent exacerbations requiring oral steroids\u00a0indicate inadequate\u00a0asthma control and should require a review of maintenance therapy. [2]", "contents": "Asthma Medication in Children -- Issues of Concern -- Asthma Exacerbation. In young children, suspension is better tolerated and accepted than tablets. In addition, for children aged 0 to 4 years with a history of previous severe exacerbations, a short course of oral systemic corticosteroids is advised.\u00a0Frequent exacerbations requiring oral steroids\u00a0indicate inadequate\u00a0asthma control and should require a review of maintenance therapy. [2]"}
{"id": "article-17921_44", "title": "Asthma Medication in Children -- Issues of Concern -- FeNO Testing and Pharmacotherapy", "content": "FeNO can be conducted in primary care settings and predict corticosteroid response.\u00a0FeNO testing is not a replacement for standard\u00a0assessment\u00a0and should not be used in isolation to estimate disease\u00a0activity and forecast future exacerbation. In addition, the costs associated with equipment and supply can restrict the utility\u00a0of FeNO\u00a0in the primary care office setting. Moreover, analysis requires experienced immunologists or pulmonologists to interpret the results. According to\u00a0NHLBI guidelines,\u00a0ICS should not be\u00a0stopped only based on low FeNO levels. [6]", "contents": "Asthma Medication in Children -- Issues of Concern -- FeNO Testing and Pharmacotherapy. FeNO can be conducted in primary care settings and predict corticosteroid response.\u00a0FeNO testing is not a replacement for standard\u00a0assessment\u00a0and should not be used in isolation to estimate disease\u00a0activity and forecast future exacerbation. In addition, the costs associated with equipment and supply can restrict the utility\u00a0of FeNO\u00a0in the primary care office setting. Moreover, analysis requires experienced immunologists or pulmonologists to interpret the results. According to\u00a0NHLBI guidelines,\u00a0ICS should not be\u00a0stopped only based on low FeNO levels. [6]"}
{"id": "article-17921_45", "title": "Asthma Medication in Children -- Issues of Concern -- Comorbidities", "content": "Comorbidities such as chronic rhinosinusitis, obesity,\u00a0gastroesophageal\u00a0reflux\u00a0disease (GERD), and\u00a0obstructive sleep apnea\u00a0are associated with\u00a0flare-ups and poor quality of life.\u00a0Treatment\u00a0of comorbid conditions is essential; however, management can complicate treatment adherence and asthma control due to polypharmacy. [52]", "contents": "Asthma Medication in Children -- Issues of Concern -- Comorbidities. Comorbidities such as chronic rhinosinusitis, obesity,\u00a0gastroesophageal\u00a0reflux\u00a0disease (GERD), and\u00a0obstructive sleep apnea\u00a0are associated with\u00a0flare-ups and poor quality of life.\u00a0Treatment\u00a0of comorbid conditions is essential; however, management can complicate treatment adherence and asthma control due to polypharmacy. [52]"}
{"id": "article-17921_46", "title": "Asthma Medication in Children -- Issues of Concern -- Bronchial Thermoplasty (BT)", "content": "Bronchial thermoplasty\u00a0has not been extensively evaluated in pediatric patients;\u00a0consequently,\u00a0BT is not recommended in children. [53]", "contents": "Asthma Medication in Children -- Issues of Concern -- Bronchial Thermoplasty (BT). Bronchial thermoplasty\u00a0has not been extensively evaluated in pediatric patients;\u00a0consequently,\u00a0BT is not recommended in children. [53]"}
{"id": "article-17921_47", "title": "Asthma Medication in Children -- Issues of Concern -- Peak Expiratory Flow (PEF) and Spirometry", "content": "PEF and spirometry are commonly used to estimate airflow obstruction and reversibility. GINA suggests the use of PEF or spirometry in the diagnosis of asthma in children aged over\u00a05. However, EF and spirometry are not feasible in children aged 1 to 4 years.", "contents": "Asthma Medication in Children -- Issues of Concern -- Peak Expiratory Flow (PEF) and Spirometry. PEF and spirometry are commonly used to estimate airflow obstruction and reversibility. GINA suggests the use of PEF or spirometry in the diagnosis of asthma in children aged over\u00a05. However, EF and spirometry are not feasible in children aged 1 to 4 years."}
{"id": "article-17921_48", "title": "Asthma Medication in Children -- Issues of Concern -- Asthma Action Plans", "content": "An asthma action plan (AAP) is a\u00a0written\u00a0document\u00a0in which the family or caregiver\u00a0is\u00a0provided with up-to-date instructions regarding daily asthma\u00a0medications, symptoms that show asthma control deterioration, response when these symptoms are identified, and steps in the case of an emergency. [54] [55] [56] The caregivers must be confident and careful when using the asthma action plan, as they must decide on initiating treatment at the onset of deterioration. A recent study indicated that a pictographic asthma action plan could be helpful for caregivers with low health literacy. [57]", "contents": "Asthma Medication in Children -- Issues of Concern -- Asthma Action Plans. An asthma action plan (AAP) is a\u00a0written\u00a0document\u00a0in which the family or caregiver\u00a0is\u00a0provided with up-to-date instructions regarding daily asthma\u00a0medications, symptoms that show asthma control deterioration, response when these symptoms are identified, and steps in the case of an emergency. [54] [55] [56] The caregivers must be confident and careful when using the asthma action plan, as they must decide on initiating treatment at the onset of deterioration. A recent study indicated that a pictographic asthma action plan could be helpful for caregivers with low health literacy. [57]"}
{"id": "article-17921_49", "title": "Asthma Medication in Children -- Issues of Concern -- Quality of Life", "content": "Quality of life is significantly compromised in children with uncontrolled asthma. Standardized questionnaires such as the Pediatric Asthma Quality of Life Questionnaire (PAQLQ) should be used to evaluate the quality of life. A study showed that although pharmacotherapy can improve quality of life, the emotional\u00a0domain\u00a0is not addressed. Psychosocial\u00a0support\u00a0is needed in addition to standard pharmacotherapy. [58]", "contents": "Asthma Medication in Children -- Issues of Concern -- Quality of Life. Quality of life is significantly compromised in children with uncontrolled asthma. Standardized questionnaires such as the Pediatric Asthma Quality of Life Questionnaire (PAQLQ) should be used to evaluate the quality of life. A study showed that although pharmacotherapy can improve quality of life, the emotional\u00a0domain\u00a0is not addressed. Psychosocial\u00a0support\u00a0is needed in addition to standard pharmacotherapy. [58]"}
{"id": "article-17921_50", "title": "Asthma Medication in Children -- Clinical Significance", "content": "Asthma is a serious health and economic concern in the United States, costing $56 billion yearly. Uncontrolled asthma disrupts daily life and causes\u00a01 in\u00a02 children to miss at least\u00a01 day of school. This\u00a0caused about 10.5 million missed school days. [59] [60] [61] According to the CDC report, in 2021, the percentage of children aged under 18 years who currently have asthma is 6.5%.", "contents": "Asthma Medication in Children -- Clinical Significance. Asthma is a serious health and economic concern in the United States, costing $56 billion yearly. Uncontrolled asthma disrupts daily life and causes\u00a01 in\u00a02 children to miss at least\u00a01 day of school. This\u00a0caused about 10.5 million missed school days. [59] [60] [61] According to the CDC report, in 2021, the percentage of children aged under 18 years who currently have asthma is 6.5%."}
{"id": "article-17921_51", "title": "Asthma Medication in Children -- Clinical Significance", "content": "The number of emergency department visits for asthma is approximately 1.2 million.\u00a0From 2016 to 2018, the estimated prevalence of asthma was about 8.1% in children aged 0 to 17 years.\u00a0From 2016 to 2018, children with asthma\u00a0had significantly more emergency department and urgent care visits (17.9%) than adults (10.1%).", "contents": "Asthma Medication in Children -- Clinical Significance. The number of emergency department visits for asthma is approximately 1.2 million.\u00a0From 2016 to 2018, the estimated prevalence of asthma was about 8.1% in children aged 0 to 17 years.\u00a0From 2016 to 2018, children with asthma\u00a0had significantly more emergency department and urgent care visits (17.9%) than adults (10.1%)."}
{"id": "article-17921_52", "title": "Asthma Medication in Children -- Clinical Significance", "content": "In the context of the COVID-19 pandemic, it is essential to remember that CDC has recognized asthma as a risk factor for severe COVID-19. [62] In patients with severe asthma using biologic therapy,\u00a0the vaccine and the\u00a0biologics should not be administered on the same day. [63] Optimal use of pharmacotherapy according to guidelines, use of a step-wise\u00a0approach, and assessment of compliance and control at each visit can significantly reduce the morbidity, mortality, emergency room visits, and healthcare costs associated with asthma. Clinicians should also emphasize using preferred therapy at each step to optimize pharmacotherapy and minimize ADR. [64]", "contents": "Asthma Medication in Children -- Clinical Significance. In the context of the COVID-19 pandemic, it is essential to remember that CDC has recognized asthma as a risk factor for severe COVID-19. [62] In patients with severe asthma using biologic therapy,\u00a0the vaccine and the\u00a0biologics should not be administered on the same day. [63] Optimal use of pharmacotherapy according to guidelines, use of a step-wise\u00a0approach, and assessment of compliance and control at each visit can significantly reduce the morbidity, mortality, emergency room visits, and healthcare costs associated with asthma. Clinicians should also emphasize using preferred therapy at each step to optimize pharmacotherapy and minimize ADR. [64]"}
{"id": "article-17921_53", "title": "Asthma Medication in Children -- Other Issues", "content": "SABA overuse has been associated with increased risks of exacerbation. Long-term use of \u03b2-2 agonists has been associated with ischemia, heart failure, arrhythmias, and risk of sudden death. [65] A high dose of ICS is associated with systemic ADR due to increased absorption. It may increase the risk of adrenal suppression, cataracts, glaucoma, psychiatric effects, and risk of infection. [66]", "contents": "Asthma Medication in Children -- Other Issues. SABA overuse has been associated with increased risks of exacerbation. Long-term use of \u03b2-2 agonists has been associated with ischemia, heart failure, arrhythmias, and risk of sudden death. [65] A high dose of ICS is associated with systemic ADR due to increased absorption. It may increase the risk of adrenal suppression, cataracts, glaucoma, psychiatric effects, and risk of infection. [66]"}
{"id": "article-17921_54", "title": "Asthma Medication in Children -- Other Issues", "content": "Patients\u00a0on chronic systemic steroids for asthma have a suppression of the hypothalamic-pituitary-adrenal (HPA) axis. A sudden withdrawal of steroids can result in adrenal insufficiency. Steroid withdrawal syndrome is marked by malaise, postural hypotension, generalized weakness, arthralgia, headaches, mood swings, and emotional lability and can be life-threatening if not recognized promptly. A gradual steroid taper is recommended. [67]", "contents": "Asthma Medication in Children -- Other Issues. Patients\u00a0on chronic systemic steroids for asthma have a suppression of the hypothalamic-pituitary-adrenal (HPA) axis. A sudden withdrawal of steroids can result in adrenal insufficiency. Steroid withdrawal syndrome is marked by malaise, postural hypotension, generalized weakness, arthralgia, headaches, mood swings, and emotional lability and can be life-threatening if not recognized promptly. A gradual steroid taper is recommended. [67]"}
{"id": "article-17921_55", "title": "Asthma Medication in Children -- Other Issues", "content": "Theophylline has a narrow therapeutic index. Theophylline toxicity presents with hypotension, cardiac arrhythmias, and seizures. Hypotension requires aggressive fluid resuscitation and vasopressors.\u00a0IV benzodiazepines are used for seizures. Phenobarbital is used for refractory seizures. In a life-threatening overdose, hemodialysis is indicated. [68] Omalizumab is associated with rare cases of anaphylaxis. Dupilumab is associated with rare cases of eosinophilic granulomatosis with polyangiitis. (EGPA or Churg-Strauss Syndrome). [7] [69]", "contents": "Asthma Medication in Children -- Other Issues. Theophylline has a narrow therapeutic index. Theophylline toxicity presents with hypotension, cardiac arrhythmias, and seizures. Hypotension requires aggressive fluid resuscitation and vasopressors.\u00a0IV benzodiazepines are used for seizures. Phenobarbital is used for refractory seizures. In a life-threatening overdose, hemodialysis is indicated. [68] Omalizumab is associated with rare cases of anaphylaxis. Dupilumab is associated with rare cases of eosinophilic granulomatosis with polyangiitis. (EGPA or Churg-Strauss Syndrome). [7] [69]"}
{"id": "article-17921_56", "title": "Asthma Medication in Children -- Enhancing Healthcare Team Outcomes", "content": "The diagnosis and management of asthma in children are complex. Asthma management involves a multi-faceted approach, including medication, education, skills training, clinical monitoring, and environmental control measures when necessary. The goals of asthma management include\u00a0enhanced quality of life, control of asthma symptoms, and\u00a0minimized\u00a0risks from exacerbations and medication side effects. [70]", "contents": "Asthma Medication in Children -- Enhancing Healthcare Team Outcomes. The diagnosis and management of asthma in children are complex. Asthma management involves a multi-faceted approach, including medication, education, skills training, clinical monitoring, and environmental control measures when necessary. The goals of asthma management include\u00a0enhanced quality of life, control of asthma symptoms, and\u00a0minimized\u00a0risks from exacerbations and medication side effects. [70]"}
{"id": "article-17921_57", "title": "Asthma Medication in Children -- Enhancing Healthcare Team Outcomes", "content": "Pediatricians usually prescribe medications for asthma in children. Immunologists or asthma specialists should be consulted at the\u00a0appropriate\u00a0step for using\u00a0novel biologic therapies. Pharmacists should verify dosing, check for interactions, and ensure medication reconciliation. Pediatric nurses should monitor growth and adverse effects at every visit.\u00a0Admission to the PICU (pediatric intensive care unit) or neonatal intensive\u00a0care unit (NICU) may be\u00a0required for severe asthma exacerbation. Pediatric hospitalists, pulmonologists, and neonatologists are crucial in managing severe asthma exacerbation and management complications.", "contents": "Asthma Medication in Children -- Enhancing Healthcare Team Outcomes. Pediatricians usually prescribe medications for asthma in children. Immunologists or asthma specialists should be consulted at the\u00a0appropriate\u00a0step for using\u00a0novel biologic therapies. Pharmacists should verify dosing, check for interactions, and ensure medication reconciliation. Pediatric nurses should monitor growth and adverse effects at every visit.\u00a0Admission to the PICU (pediatric intensive care unit) or neonatal intensive\u00a0care unit (NICU) may be\u00a0required for severe asthma exacerbation. Pediatric hospitalists, pulmonologists, and neonatologists are crucial in managing severe asthma exacerbation and management complications."}
{"id": "article-17921_58", "title": "Asthma Medication in Children -- Enhancing Healthcare Team Outcomes", "content": "In case of toxicity, consultation with a medical toxicologist may be essential.\u00a0The interprofessional approach\u00a0from clinicians (MD, DO, NP, PA), toxicologists, pediatric pharmacists, respiratory therapists, and specialty-trained nurses improves the treatment efficacy and optimizes the outcomes\u00a0in the treatment of pediatric asthma.", "contents": "Asthma Medication in Children -- Enhancing Healthcare Team Outcomes. In case of toxicity, consultation with a medical toxicologist may be essential.\u00a0The interprofessional approach\u00a0from clinicians (MD, DO, NP, PA), toxicologists, pediatric pharmacists, respiratory therapists, and specialty-trained nurses improves the treatment efficacy and optimizes the outcomes\u00a0in the treatment of pediatric asthma."}
{"id": "article-17921_59", "title": "Asthma Medication in Children -- Nursing, Allied Health, and Interprofessional Team Interventions", "content": "Nursing interventions and actions Checking pulse oximetry Monitor the vitals Provide oxygen if O 2 saturation is less than 90% Start at 2 liters nasal cannula Increase as needed Consult the provider and respiratory therapist if more than 6 liters of nasal cannula is required. Evaluate the patient to determine if they are receiving\u00a0adequate\u00a0oxygen. Learn triggers and ensure the room does not have any, ie, flowers, dust, animal dander, wool blankets, etc. Ensure\u00a0proper delivery of medications by nebulization Patient education about\u00a0ADR and adequate use of MDI to prevent oral candidiasis. [71] Physical therapists play an essential role in improving lung function. A study has demonstrated that physical therapy can improve\u00a0forced vital capacity (FVC). [72] Respiratory therapist-guided bronchodilator weaning based on the MPIS (modified pulmonary index score) can reduce the\u00a0hospital length of stay (LOS). [73]", "contents": "Asthma Medication in Children -- Nursing, Allied Health, and Interprofessional Team Interventions. Nursing interventions and actions Checking pulse oximetry Monitor the vitals Provide oxygen if O 2 saturation is less than 90% Start at 2 liters nasal cannula Increase as needed Consult the provider and respiratory therapist if more than 6 liters of nasal cannula is required. Evaluate the patient to determine if they are receiving\u00a0adequate\u00a0oxygen. Learn triggers and ensure the room does not have any, ie, flowers, dust, animal dander, wool blankets, etc. Ensure\u00a0proper delivery of medications by nebulization Patient education about\u00a0ADR and adequate use of MDI to prevent oral candidiasis. [71] Physical therapists play an essential role in improving lung function. A study has demonstrated that physical therapy can improve\u00a0forced vital capacity (FVC). [72] Respiratory therapist-guided bronchodilator weaning based on the MPIS (modified pulmonary index score) can reduce the\u00a0hospital length of stay (LOS). [73]"}
{"id": "article-17921_60", "title": "Asthma Medication in Children -- Nursing, Allied Health, and Interprofessional Team Monitoring", "content": "Nursing monitoring should include the following: Auscultate lung sounds If wheezing, they may need a breathing treatment. No breath sounds (silent chest) or stridor is usually ominous signs and require immediate reporting to the team leader. Crackles may have pneumonia and may need suctioning. [74] Positioning the patient in an upright position Obtain a baseline peak flow and monitor for the decline. The smaller the number, the less amount of air they are moving. Complete prescribed breathing treatments such as albuterol for bronchodilation and\u00a0tiotropium to decrease bronchospasm. Monitor the adverse drug reactions of corticosteroids. If theophylline is prescribed,\u00a0consider\u00a0therapeutic drug monitoring to prevent toxicity. [75] Make sure the entire medical team is aware if the patient is getting worse; know the location of the crash cart.", "contents": "Asthma Medication in Children -- Nursing, Allied Health, and Interprofessional Team Monitoring. Nursing monitoring should include the following: Auscultate lung sounds If wheezing, they may need a breathing treatment. No breath sounds (silent chest) or stridor is usually ominous signs and require immediate reporting to the team leader. Crackles may have pneumonia and may need suctioning. [74] Positioning the patient in an upright position Obtain a baseline peak flow and monitor for the decline. The smaller the number, the less amount of air they are moving. Complete prescribed breathing treatments such as albuterol for bronchodilation and\u00a0tiotropium to decrease bronchospasm. Monitor the adverse drug reactions of corticosteroids. If theophylline is prescribed,\u00a0consider\u00a0therapeutic drug monitoring to prevent toxicity. [75] Make sure the entire medical team is aware if the patient is getting worse; know the location of the crash cart."}
{"id": "article-17921_61", "title": "Asthma Medication in Children -- Nursing, Allied Health, and Interprofessional Team Monitoring", "content": "If the nursing\u00a0or allied health staff thinks the patient is deteriorating or airway closure may be imminent, it is better to be proactive than reactive. Contact the medical team\u00a0immediately. [76]", "contents": "Asthma Medication in Children -- Nursing, Allied Health, and Interprofessional Team Monitoring. If the nursing\u00a0or allied health staff thinks the patient is deteriorating or airway closure may be imminent, it is better to be proactive than reactive. Contact the medical team\u00a0immediately. [76]"}
{"id": "article-17921_62", "title": "Asthma Medication in Children -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Asthma Medication in Children -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}